Programs
Aeviant builds each program around a defined disease mechanism and the therapeutic behaviour required to address it. AVX-1 is described publicly in detail. AVX-2 is listed by name while its technical information remains confidential pending the relevant patent filing.
AVX-1
AVX-1 applies Aeviant’s state-dependent design approach to noradrenergic feedback. The program investigates whether positive allosteric modulation of the α2A autoreceptor can reinforce regulation while remaining dependent on the endogenous signal.
α2A-adrenergic autoreceptor · Positive allosteric modulation · Noradrenergic dysregulation · Computational design
AVX-2
Further information will be disclosed after the relevant patent filing. Until then, program details remain confidential.